Molecular markers of anti-malarial drug resistance in southwest Ethiopia over time: Regional surveillance from 2006 to 2013

Malaria Journal

Volumn 14, Issue 1, 2015, Pages

  Heuchert, Alexander ^a   Abduselam, Nuredin ^b   Zeynudin, Ahmed ^b   Eshetu, Teferi ^b   Löscher, Thomas ^a   Wieser, Andreas ^a,b,c   Pritsch, Michael ^a,c   Berens Riha, Nicole ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b UNIVERSITY OF MUNICH   (Germany)

^c German Center for Cardiovascular Research   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ARTEMETHER PLUS BENFLUMETOL; CHLOROQUINE; MOLECULAR MARKER; SARCOPLASMIC RETICULUM CALCIUM TRANSPORTING ADENOSINE TRIPHOSPHATASE; ANTIMALARIAL AGENT; ARTEMISININ DERIVATIVE; BIOLOGICAL MARKER; DRUG COMBINATION; ETHANOLAMINE DERIVATIVE; FLUORENE DERIVATIVE; PROTOZOAL PROTEIN;

ANTIMALARIAL DRUG RESISTANCE; ARTICLE; BLOOD; CODON; DISEASE SURVEILLANCE; DRUG USE; ETHIOPIA; FILTER; GENE MUTATION; GENE SEQUENCE; HUMAN; HUMAN TISSUE; MALARIA; MIXED INFECTION; PLASMODIUM FALCIPARUM; PLASMODIUM VIVAX; PREVALENCE; PROTEIN DOMAIN; REAL TIME POLYMERASE CHAIN REACTION; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SINGLE NUCLEOTIDE POLYMORPHISM; ADOLESCENT; ADULT; AGED; CHILD; DRUG COMBINATION; DRUG EFFECTS; DRUG RESISTANCE; FEMALE; GENETICS; INFANT; ISOLATION AND PURIFICATION; MALARIA, FALCIPARUM; MALARIA, VIVAX; MALE; MIDDLE AGED; PARASITOLOGY; PRESCHOOL CHILD; SEASON; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIMALARIALS; ARTEMISININS; BIOMARKERS; CHILD; CHILD, PRESCHOOL; DRUG COMBINATIONS; DRUG RESISTANCE; ETHANOLAMINES; ETHIOPIA; FEMALE; FLUORENES; HUMANS; INFANT; MALARIA, FALCIPARUM; MALARIA, VIVAX; MALE; MIDDLE AGED; PLASMODIUM FALCIPARUM; PLASMODIUM VIVAX; PREVALENCE; PROTOZOAN PROTEINS; REAL-TIME POLYMERASE CHAIN REACTION; SEASONS; YOUNG ADULT;

EID: 84930010968     PISSN: None     EISSN: 14752875     Source Type: Journal    
DOI: 10.1186/s12936-015-0723-2     Document Type: Article

References (46)

1. Gürkov R, Eshetu T, Miranda IB, Berens-Riha N, Mamo Y, Girma T, et al. Ototoxicity of artemether/lumefantrine in the treatment of falciparum malaria: a randomized trial. Malar J. 2008;7:179.
2. Djimdé A, Doumbo OK, Cortese JF, Kayentao K, Doumbo S, Diourté Y, et al. A molecular marker for chloroquine-resistant falciparum malaria. N Engl J Med. 2001;344:257-63.
3. Schneider AG, Premji Z, Felger I, Smith T, Abdulla S, Beck HP, et al. A point mutation in codon 76 of pfcrt of P. falciparum is positively selected for by Chloroquine treatment in Tanzania. Infect Genet Evol. 2002;1:183-9.
4. Sidhu AB, Verdier-Pinard D, Fidock DA. Chloroquine resistance in Plasmodium falciparum malaria parasites conferred by pfcrt mutations. Science. 2002;298:210-3.
5. Foote SJ, Thompson JK, Cowman AF, Kemp DJ. Amplification of the multidrug resistance gene in some chloroquine-resistant isolates of P. falciparum. Cell. 1989;57:921-30.
6. Cowman AF, Karcz S, Galatis D, Culvenor JG. A P-glycoprotein homologue of Plasmodium falciparum is localized on the digestive vacuole. J Cell Biol. 1991;113:1033-42.
7. Sisowath C, Strömberg J, Mårtensson A, Msellem M, Obondo C, Björkman A, et al. In vivo selection of Plasmodium falciparum pfmdr1 86 N coding alleles by artemether-lumefantrine (Coartem). J Infect Dis. 2005;191:1014-7.
8. Sisowath C, Ferreira PE, Bustamante LY, Dahlström S, Mårtensson A, Björkman A, et al. The role of pfmdr1 in Plasmodium falciparum tolerance to artemether-lumefantrine in Africa. Trop Med Int Health. 2007;12:736-42.
9. Dokomajilar C, Nsobya SL, Greenhouse B, Rosenthal PJ, Dorsey G. Selection of Plasmodium falciparum pfmdr1 alleles following therapy with artemether-lumefantrine in an area of Uganda where malaria is highly endemic. Antimicrob Agents Chemother. 2006;50:1893-5.
10. Happi CT, Gbotosho GO, Folarin OA, Sowunmi A, Hudson T, O'Neil M, et al. Selection of Plasmodium falciparum multidrug resistance gene 1 alleles in asexual stages and gametocytes by artemether-lumefantrine in Nigerian children with uncomplicated falciparum malaria. Antimicrob Agents Chemother. 2009;53:888-95.
11. Imwong M, Dondorp AM, Nosten F, Yi P, Mungthin M, Hanchana S, et al. Exploring the contribution of candidate genes to artemisinin resistance in Plasmodium falciparum. Antimicrob Agents Chemother. 2010;54:2886-92.
12. Roepe PD. Molecular and physiologic basis of quinoline drug resistance in Plasmodium falciparum malaria. Future Microbiol. 2009;4:441-55.
13. Pickard AL, Wongsrichanalai C, Purfield A, Kamwendo D, Emery K, Zalewski C, et al. Resistance to antimalarials in Southeast Asia and genetic polymorphisms in pfmdr1. Antimicrob Agents Chemother. 2003;47:2418-23.
14. Price RN, Uhlemann AC, Brockman A, McGready R, Ashley E, Phaipun L, et al. Mefloquine resistance in Plasmodium falciparum and increased pfmdr1 gene copy number. The Lancet. 2004;364:438-47.
15. Price RN, Uhlemann AC, van Vugt M, Brockman A, Hutagalung R, Nair S, et al. Molecular and pharmacological determinants of the therapeutic response to artemether-lumefantrine in multidrug-resistant Plasmodium falciparum malaria. Clin Infect Dis. 2006;42:1570-7.
16. Holmgren G, Björkman A, Gil JP. Amodiaquine resistance is not related to rare findings of pfmdr1 gene amplifications in Kenya. Trop Med Int Health. 2006;11:1808-12.
17. Eckstein-Ludwig U, Webb RJ, Van Goethem ID, East JM, Lee AG, Kimura M, et al. Artemisinins target the SERCA of Plasmodium falciparum. Nature. 2003;424:957-61.
18. Krishna S, Uhlemann AC, Haynes RK. Artemisinins: mechanisms of action and potential for resistance. Drug Resist Updat. 2004;7:233-44.
19. Krishna S, Woodrow CJ, Staines HM, Haynes RK, Mercereau-Puijalon O. Re-evaluation of how artemisinins work in light of emerging evidence of in vitro resistance. Trends Mol Med. 2006;12:200-5.
20. Jambou R, Legrand E, Niang M, Khim N, Lim P, Volney B, et al. Resistance of Plasmodium falciparum field isolates to in-vitro artemether and point mutations of the SERCA-type PfATPase6. Lancet. 2005;366:1960-63.
21. Menegon M, Sannella AR, Majori G, Severini C. Detection of novel point mutations in the Plasmodium falciparum ATPase6 candidate gene for resistance to artemisinins. Parasitol Int. 2008;57:233-5.
22. Jambou R, Martinelli A, Pinto J, Gribaldo S, Legrand E, Niang M, et al. Geographic structuring of the Plasmodium falciparum sarco(endo)plasmic reticulum Ca2+ ATPase (PfSERCA) gene diversity. PLoS One. 2010;5:e9424.
23. Zakeri S, Hemati S, Pirahmadi S, Afsharpad M, Raeisi A, Djadid ND. Molecular assessment of atpase6 mutations associated with artemisinin resistance among unexposed and exposed Plasmodium falciparum clinical isolates to artemisinin-based combination therapy. Malar J. 2012;11:373.
24. Ariey F, Witkowski B, Amaratunga C, Beghain J, Langlois AC, Khim N, et al. A molecular marker of artemisinin-resistant Plasmodium falciparum malaria. Nature. 2014;505:50-5.
25. Adams J, Kelso R, Cooley L. The kelch repeat superfamily of proteins: propellers of cell function. Trends Cell Biol. 2000;10:17-24.
26. Prag S, Adams JC. Molecular phylogeny of the kelch-repeat superfamily reveals an expansion of BTB/kelch proteins in animals. BMC Bioinformatics. 2003;4:42.
27. Brega S, Meslin B, de Monbrison F, Severini C, Gradoni L, Udomsangpetch R, et al. Identification of the Plasmodium vivax mdr-like gene (pvmdr1) and analysis of single-nucleotide polymorphisms among isolates from different areas of endemicity. J Infect Dis. 2005;191:272-7.
28. Suwanarusk R, Russell B, Chavchich M, Chalfein F, Kenangalem E, Kosaisavee V, et al. Chloroquine resistant Plasmodium vivax: in vitro characterisation and association with molecular polymorphisms. PLoS One. 2007;2:e1089.
29. Marfurt J, de Monbrison F, Brega S, Barbollat L, Müller I, Sie A, et al. Molecular markers of in vivo Plasmodium vivax resistance to amodiaquine plus sulfadoxine-pyrimethamine: mutations in pvdhfr and pvmdr1. J Infect Dis. 2008;198:409-17.
30. Schunk M, Kumma WP, Miranda IB, Osman ME, Roewer S, Alano A, et al. High prevalence of drug-resistance mutations in Plasmodium falciparum and Plasmodium vivax in southern Ethiopia. Malar J. 2006;5:54.
31. Eshetu T, Berens-Riha N, Fekadu S, Tadesse Z, Gürkov R, Hölscher M, et al. Different mutation patterns of Plasmodium falciparum among patients in Jimma University Hospital, Ethiopia. Malar J. 2010;9:226.
32. Venkatesan M, Gadalla NB, Stepniewska K, Dahal P, Nsanzabana C, Moriera C, et al. Polymorphisms in Plasmodium falciparum chloroquine resistance transporter and multidrug resistance 1 genes: parasite risk factors that affect treatment outcomes for P. falciparum malaria after artemether-lumefantrine and artesunate-amodiaquine. Am J Trop Med Hyg. 2014;91:833-43.
33. Kain KC, Lanar DE. Determination of genetic variation within Plasmodium falciparum by using enzymatically amplified DNA from filter paper disks impregnated with whole blood. J Clin Microbiol. 1991;29:1171-4.
34. Snounou G, Viriyakosol S, Jarra W, Thaithong S, Brown KN. Identification of the four human malaria parasite species in field samples by the polymerase chain reaction and detection of a high prevalence of mixed infections. Mol Biochem Parasitol. 1993;58:283-92.
35. Berens N, Schwoebel B, Jordan S, Vanisaveth V, Phetsouvanh R, Christophel EM, et al. Plasmodium falciparum: correlation of in vivo resistance to chloroquine and antifolates with genetic polymorphisms in isolates from the south of Lao PDR. Trop Med Int Health. 2003;8:775-82.
36. Purfield A, Nelson A, Laoboonchai A, Congpuong K, McDaniel P, Miller RS, et al. A new method for detection of pfmdr1 mutations in Plasmodium falciparum DNA using real-time PCR. Malar J. 2004;3:9.
37. Basic Local Alignment Search Tool (BLAST), National Center for Biotechnology Information [http://www.ncbi.nlm.nih.gov/Blast.cgi]
38. GenBank. NIH genetic sequence database. National Center for Biotechnology Information [http://www.ncbi.nlm.nih.gov/genbank]
39. WHO. Global report on antimalarial drug efficacy and drug resistance: 2000 - 2010. Geneva, World Health Organization, 2010. [http://whqlibdoc.who.int/publications/2010/9789241500470-eng.pdf]
40. Eshetu T, Abdo N, Bedru KH, Fekadu S, Wieser A, Pritsch M, et al. Open-label trial with artemether-lumefantrine against uncomplicated Plasmodium falciparum malaria three years after its broad introduction in Jimma Zone, Ethiopia. Malar J. 2012;11:240.
41. Abreha T, Alemayehu B, Tadesse Y, Gebresillassie S, Tadesse A, Demeke L, et al. Malaria diagnostic capacity in health facilities in Ethiopia. Malar J. 2014;13:292.
42. Lobo E, de Sousa B, Rosa S, Figueiredo P, Lobo L, Pateira S, et al. Prevalence of pfmdr1 alleles associated with artemether-lumefantrine tolerance/resistance in Maputo before and after the implementation of artemisinin-based combination therapy. Malar J. 2014;13:300.
43. Mekonnen SK, Aseffa A, Berhe N, Teklehaymanot T, Clouse RM, Gebru T, et al. Return of chloroquine-sensitive Plasmodium falciparum parasites and emergence of chloroquine-resistant Plasmodium vivax in Ethiopia. Malar J. 2014;13:244.
44. Teka H, Petros B, Yamuah L, Tesfaye G, Elhassan I, Muchohi S, et al. Chloroquine-resistant Plasmodium vivax malaria in Debre Zeit, Ethiopia. Malar J. 2008;7:220.
45. Ketema T, Bacha K, Birhanu T, Petros B. Chloroquine-resistant Plasmodium vivax malaria in Serbo town, Jimma zone, south-west Ethiopia. Malar J. 2009;8:177.
46. Yohannes AM, Teklehaimanot A, Bergqvist Y, Ringwald P. Confirmed vivax resistance to chloroquine and effectiveness of artemether-lumefantrine for the treatment of vivax malaria in Ethiopia. Am J Trop Med Hyg. 2011;84:137-40.